Imunon

Researchers are developing innovative non-viral delivery systems for IL-12 immunotherapy, targeting the tumor microenvironment while minimizing systemic toxicity in ovarian cancer treatment.

Imunon's novel DNA plasmid vaccine demonstrated a favorable safety profile with no serious adverse events reported in the clinical trial.

IMNN-101, a novel DNA-based COVID-19 vaccine, demonstrated a 2-4 fold increase in neutralizing antibody titers through Week 4 in Phase 1 trial participants.

Imunon's IMNN-001, combined with chemotherapy, demonstrated an 11.1-month improvement in overall survival in patients with advanced ovarian cancer in the OVATION-2 trial.

IMUNON's IMNN-001, combined with standard chemotherapy, demonstrated a 35% improvement in overall survival for advanced ovarian cancer patients compared to chemotherapy alone.

IMUNON's IMNN-001 demonstrated an 11.1-month overall survival improvement in advanced ovarian cancer patients compared to standard of care, marking a significant clinical advancement.

IMUNON has secured FDA alignment on its Chemistry, Manufacturing, and Controls (CMC) strategy for IMNN-001, an immunotherapy targeting advanced ovarian cancer.

IMUNON's IMNN-001 Phase 2 OVATION 2 study showed an 11.1-month increase in median overall survival compared to standard care for ovarian cancer patients.

IMUNON will host an Ovarian Cancer R&D Day on September 18, 2024, featuring updates on IMNN-001, an investigational therapy for ovarian cancer.

IMUNON's IMNN-001, combined with bevacizumab, is being evaluated in a Phase 1/2 clinical trial for advanced ovarian cancer patients undergoing frontline neoadjuvant therapy.